| Severity of mitral and aortic regurgitation as assessed by cardiovascular magnetic resonance: optimizing correlation with Doppler echocardiography EV Gelfand, S Hughes, TH Hauser, SB Yeon, L Goepfert, KV Kissinger, ... Journal of Cardiovascular Magnetic Resonance 8 (3), 503-507, 2006 | 277 | 2006 |
| Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13307 patients in five … CM Gibson, RL Dumaine, EV Gelfand, SA Murphy, DA Morrow, SD Wiviott, ... European heart journal 25 (22), 1998-2005, 2004 | 213 | 2004 |
| Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors EV Gelfand, CP Cannon Journal of the American College of Cardiology 47 (10), 1919-1926, 2006 | 197 | 2006 |
| Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors EV Gelfand, CP Cannon Expert Opinion on Investigational Drugs 15 (3), 307-315, 2006 | 97 | 2006 |
| Comparison of intracardiac echocardiography and transesophageal echocardiography for imaging of the right and left atrial appendages E Anter, J Silverstein, CM Tschabrunn, A Shvilkin, CI Haffajee, ... Heart Rhythm 11 (11), 1890-1897, 2014 | 82 | 2014 |
| Association of TIMI myocardial perfusion grade and ST-segment resolution with cardiovascular magnetic resonance measures of microvascular obstruction and infarct size following … E Appelbaum, AJ Kirtane, A Clark, YB Pride, EV Gelfand, CJ Harrigan, ... Journal of Thrombosis and Thrombolysis 27, 123-129, 2009 | 53 | 2009 |
| Valvular heart disease: classic teaching and emerging paradigms DM Brinkley, EV Gelfand The American journal of medicine 126 (12), 1035-1042, 2013 | 36 | 2013 |
| Management of acute coronary syndromes EV Gelfand, CP Cannon Wiley-Blackwell, 2009 | 35 | 2009 |
| Venous thromboembolism guidebook EV Gelfand, G Piazza, SZ Goldhaber Critical Pathways in Cardiology 2 (4), 247-265, 2003 | 32 | 2003 |
| Antibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT EV Gelfand, CP Cannon American heart journal 2 (147), 202-209, 2004 | 30 | 2004 |
| Myocardial infarction: contemporary management strategies EV Gelfand, CP Cannon Journal of internal medicine 262 (1), 59-77, 2007 | 25 | 2007 |
| Predictors of preserved left ventricular systolic function after surgery for chronic organic mitral regurgitation: a prospective study EV Gelfand, JA Haffajee, TH Hauser, SB Yeon, L Goepfert, KV Kissinger, ... Journal of Heart Valve Disease 19 (1), 43, 2010 | 24 | 2010 |
| Effects of N-acetyl-cysteine on endothelial function and inflammation in patients with type 2 diabetes mellitus A Jeremias, G Soodini, E Gelfand, Y Xu, RC Stanton, ES Horton, ... Heart International 4 (1), hi. 2009. e7, 2009 | 24 | 2009 |
| Left atrial size and postoperative atrial fibrillation: the volume of evidence suggests it is time to break an old habit WJ Manning, EV Gelfand Journal of the American College of Cardiology 48 (4), 787-789, 2006 | 22 | 2006 |
| Recovery of giant-cell myocarditis using combined cytolytic immunosuppression and mechanical circulatory support D Steinhaus, E Gelfand, PA VanderLaan, RD Kociol The Journal of Heart and Lung Transplantation 33 (7), 769-771, 2014 | 15 | 2014 |
| Venous thromboembolism guidebook EV Gelfand, G Piazza, SZ Goldhaber Critical Pathways in Cardiology 1 (1), 26-43, 2002 | 14 | 2002 |
| Cardiovascular magnetic resonance imaging for valvular heart disease A Morello, EV Gelfand Current heart failure reports 6 (3), 160-166, 2009 | 13 | 2009 |
| Images in cardiovascular medicine. Sinus of Valsalva aneurysm with right ventricular outflow tract obstruction: evaluation with Doppler, real-time 3-dimensional and contrast … EV Gelfand, D Bzymek, MT Johnstone Circulation 115 (2), e16-7, 2007 | 10 | 2007 |
| Pathophysiology of acute coronary syndromes AB Rosen, EV Gelfand Management of acute coronary syndromes, 1-12, 2009 | 6 | 2009 |
| Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients CT Dibble, EV Gelfand, CP Cannon Current atherosclerosis reports 9, 359-366, 2007 | 6 | 2007 |
Christopher P. CannonProfessor of Medicine, Harvard Medical School, Brigham and Women's Hospital在 bwh.harvard.edu 的电子邮件经过验证
